Cargando…
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
Venous thromboembolism (VTE) complicates the clinical course of approximately 5–10% of all cancer patients. Anticoagulation of the cancer patient often presents unique challenges as these patients have both a higher risk of recurrent VTE and a higher risk of bleeding than patients without cancer. Al...
Autores principales: | Al-Samkari, Hanny, Connors, Jean M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115910/ https://www.ncbi.nlm.nih.gov/pubmed/30111746 http://dx.doi.org/10.3390/cancers10080271 |
Ejemplares similares
-
Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
por: Song, Andrew B, et al.
Publicado: (2019) -
Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis
por: Attard, Laura M, et al.
Publicado: (2022) -
Cancer‐associated thrombosis: Role of direct oral anticoagulants
por: Ikeda, Masataka, et al.
Publicado: (2018) -
Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients
por: Leiva, Orly, et al.
Publicado: (2020) -
The Role of Direct Oral Anticoagulants in Cancer-Associated Thrombosis According to the Current Literature
por: Nana, Petroula, et al.
Publicado: (2021)